Daron Evans Buys 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans acquired 10,000 shares of Rezolute stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the purchase, the chief financial officer now directly owns 150,900 shares in the company, valued at $647,361. The trade was a 7.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daron Evans also recently made the following trade(s):

• On Thursday, December 12th, Daron Evans bought 9,000 shares of Rezolute stock. The stock was purchased at an average price of $4.60 per share, for a total transaction of $41,400.00.

Rezolute Stock Performance

Shares of Rezolute stock opened at $4.08 on Thursday. The firm has a market cap of $236.41 million, a PE ratio of -3.21 and a beta of 1.01. The business’s 50 day simple moving average is $5.14 and its 200 day simple moving average is $4.78. Rezolute, Inc. has a 52-week low of $0.86 and a 52-week high of $6.19.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). As a group, equities research analysts predict that Rezolute, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on RZLT. Wedbush reissued an “outperform” rating and issued a $112.00 price target on shares of Rezolute in a report on Monday, November 4th. Guggenheim began coverage on Rezolute in a research note on Tuesday, August 27th. They issued a “buy” rating and a $11.00 target price for the company. BTIG Research increased their price target on Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. JMP Securities reiterated a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Finally, HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Rezolute in a research note on Friday, November 8th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Rezolute currently has a consensus rating of “Buy” and an average price target of $24.13.

Institutional Investors Weigh In On Rezolute

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jeppson Wealth Management LLC acquired a new position in shares of Rezolute during the 2nd quarter worth about $45,000. MML Investors Services LLC acquired a new stake in shares of Rezolute in the third quarter valued at about $57,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Rezolute during the third quarter worth about $65,000. Virtu Financial LLC boosted its position in Rezolute by 58.0% during the third quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock valued at $126,000 after purchasing an additional 9,551 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in Rezolute by 205.8% in the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock valued at $145,000 after purchasing an additional 22,660 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.